Interleukin-13

Eli Lilly and Company announced it received FDA approval for Ebglyss for the treatment of moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies, according to a company press release.

The Th2 cytokine IL-13 appeared to play a significant role in protecting people with allergic asthma against the damaging effects of SARS-CoV-2 infection, according to a study published in Proceedings of the National Academy of Sciences.

LEO Pharma announced that tralokinumab met all primary and secondary endpoints in ECZTRA 1-3, its three pivotal phase 3 studies for moderate to severe atopic dermatitis in adults.

Preliminary findings from Emma Guttman-Yassky, MD, PhD, and colleagues demonstrate a novel use of dupilumab for managing chronic keloids with reductions in skin fibrosis and keloidal scarring, which may suggest a potential underlying Th2 pathogenesis in keloid formation.

Interleukin-13 may be the central cytokine in the skin of patients with atopic dermatitis, and by blocking interleukin-13 with targeted therapies it is possible to block many key disease characteristics such as skin barrier deficiency, according to research presented at European Academy of Dermatology and Venereology Congress.

Dermira announced treatment commencement in the first patient for a phase 3 study evaluating lebrikizumab in adult and adolescents with moderate to severe atopic dermatitis.

Researchers have found a way to evaluate the cutaneous biomarkers of atopic dermatitis via a minimally invasive method using tape strips, which may offer insight into tracking pediatric treatment responses in the future, according to recent findings published in JAMA Dermatology.

Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to a pooled analysis of three phase 3 trials.